# A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

> **NCT07543744** · PHASE1 · RECRUITING · sponsor: **R-Pharm** · enrollment: 180 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** RPH-030
- **DRUG:** Vectibix®
- **DRUG:** Irinotecan
- **DRUG:** Calcium Folinate
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT07543744
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2026-05-15
- **Final completion:** 2028-08
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543744, "A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*